Skip to main content

Promega Asks Court to Stop Benitec from Licensing RNAi Technology

NEW YORK, Nov. 11 (GenomeWeb News) - Promega has filed a motion with the US District Court of Delaware seeking an injunction to stop Benitec from granting further licenses to ddRNAi technology to which it claims exclusivity.

The motion is the latest move in row between the two companies over rights to the RNAi technology. In July, Benitec sued Promega, which had acquired the exclusive rights to use and sublicense the ddRNAi technology in areas outside human therapeutics in exchange for $350,000 and royalties.

The suit claims that Promega had failed to meet its payment requirements to Benitec, and therefore had forfeited its exclusive rights to the technology in lieu of a non-exclusive license to simply use the technology.

Promega's motion follows Benitec's announcment in October that it had granted Artemis Pharmaceuticals of Cologne, Germany, a non-exclusive commercial license to use Benitec's ddRNAi technology.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.